Empagliflozinin Sıçanlarda Doksorubisin ile Oluşturulan Kardiyomiyopati Üzerine Etkisi
View/ Open
Date
2021-07-12Author
Barış, Veysel Özgür
xmlui.dri2xhtml.METS-1.0.item-emb
Acik erisimxmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Barış V.Ö. Empagliflozin’s Effect on Doxorubicin induced Cardiyomyopathy in
Rats Hacettepe University Graduate School of Health Sciences, Doctor of
Philosophy Thesis for Physiology, Ankara, 2021 Empagliflozin is an SGLT-2
inhibitor that reduces cardiovascular deaths and hospitalizations for heart failure. In
this study, we aimed to evaluate the possible protective effects of empagliflozin
against doxorubicin-induced cardiotoxicity. Non-diabetic Sprague-Dawley rats were
randomly divided into four groups in this study. Physiological saline (SF) (1 ml) was
given to the control group by intraperitoneal (I.P.) and orogastric (O.G.) routes, and
to the EMPA group empagliflozin 10 mg/kg/day by O.G. route, SF was given by I.P.
route. DOX group as a cumulative 18 mg / kg body weight / 6 days doxorubicin by
IP route, SF was given via O.G. route. Doxorubicin and empagliflozin were
administered at the same doses for 14 days to the DOX + EMPA group. On the 15th
day, echocardiographic and electrocardiographic examinations were performed under
anesthesia. Blood samples were taken to evaluate biochemical parameters and heart
tissues were excised to evaluate histopathological findings. Left ventricular systolic
(P <0.05) and diastolic diameters (P <0.01), QTc interval (P <0.001), karyololysis
and karyorexis ratio (P <0.001) and infiltrative cell proliferation (P < 0.01) in the
DOX group compared to the control group 0.001), while left ventricular ejection
fraction, fractional shortening and normal cell morphology were found to be lower (P
<0.001). In the DOX + EMPA group; Compared to the Dox group, left ventricular
diastolic diameters (P <0.05) and systolic (P <0.01) diameters, QTc interval (P
<0.001), karyolysis and karyorexis rates (P <0.001) and infiltrative cell proliferation
were significantly lower. (P < 0.01); normal cell morphology and left ventricular
ejection fraction were significantly higher than in the DOX group (P <0.001).
Biochemical results were similar between groups. As a result; This study showed that
empagliflozin significantly improved doxorubicin-induced QTc prolongation, left
ventricular dilatation, left ventricular systolic dysfunction, infiltrative cell
proliferation and necrosis. The data obtained in the current study indicate that the
protective effect of empagliflozin is due to the increase in mitochondrial biogenesis
and prevention of sarcoplasmic reticulum degeneration rather than natriuretic or
antioxidant effects.
xmlui.mirage2.itemSummaryView.Collections
The following license files are associated with this item: